Results 11 to 20 of about 70,211 (203)
AFF3 upregulation mediates tamoxifen resistance in breast cancers [PDF]
Journal of Experimental & Clinical Cancer Research, 2018 Background Although tamoxifen is a highly effective drug for treating estrogen receptor–positive (ER+) breast cancer, nearly all patients with metastasis with initially responsive tumors eventually relapse, and die from acquired drug resistance ...
Yawei Shi +7 more
doaj +3 more sources
Mechanisms of tamoxifen resistance [PDF]
Endocrine-Related Cancer, 2004 The anti-oestrogen tamoxifen is the most commonly used treatment for patients with oestrogen-receptor (ER)-positive breast cancer. Although many patients benefit from tamoxifen in the adjuvant and metastatic settings, resistance is an important clinical problem. The target of tamoxifen in vivo is the ER.
Alistair, Ring, Mitch, Dowsett
openaire +2 more sources
Pathways to tamoxifen resistance [PDF]
Cancer Letters, 2007 Therapies that target the synthesis of estrogen or the function of estrogen receptor(s) have been developed to treat breast cancer. While these approaches have proven to be beneficial to a large number of patients, both de novo and acquired resistance to these drugs is a significant problem.
Rebecca B, Riggins +3 more
openaire +2 more sources
Clonal selection in tamoxifen resistance [PDF]
Cancer Biology & Therapy, 2010 Commentary to:MCF-7 breast cancer cells selected for tamoxifen resistance acquire new phenotypes differing in DNA content, phospho-HER2 and PAX2 expression, and rapamycin sensitivityEuphemia Leung, Nagarajan Kannan, Geoffrey W. Krissansen, Michael P.
Kideok, Jin, Saraswati, Sukumar
openaire +2 more sources
Resuming Sensitivity of Tamoxifen-Resistant Breast Cancer Cells to Tamoxifen by Tetrandrine [PDF]
Integrative Cancer Therapies, 2021 Background: Tamoxifen is one of the medicines for adjuvant endocrine therapy of hormone-dependent breast cancer. However, development of resistance to tamoxifen occurs inevitably during treatment. This study aimed to determine whether sensitivity of tamoxifen-resistant breast cancer cells (TAM-R) could be reinstated by tetrandrine (Tet).
Yuntao Wang +5 more
openaire +3 more sources
Tamoxifen Resistance: Emerging Molecular Targets [PDF]
International Journal of Molecular Sciences, 2016 17β-Estradiol (E2) plays a pivotal role in the development and progression of breast cancer. As a result, blockade of the E2 signal through either tamoxifen (TAM) or aromatase inhibitors is an important therapeutic strategy to treat or prevent estrogen receptor (ER) positive breast cancer.
Milena Rondón-Lagos +4 more
openaire +2 more sources
Progress in the Understanding of the Mechanism of Tamoxifen Resistance in Breast Cancer
Frontiers in Pharmacology, 2020 Tamoxifen is a drug commonly used in the treatment of breast cancer, especially for postmenopausal patients. However, its efficacy is limited by the development of drug resistance. Downregulation of estrogen receptor alpha (ERα) is an important mechanism
Jingwei Yao +7 more
doaj +1 more source
Inhibition of STAT3 enhances sensitivity to tamoxifen in tamoxifen-resistant breast cancer cells [PDF]
BMC Cancer, 2021 Abstract Background The mechanisms of endocrine resistance are complex, and deregulation of several oncogenic signalling pathways has been proposed. We aimed to investigate the role of the EGFR and Src-mediated STAT3 signalling pathway in tamoxifen-resistant breast cancer cells. Methods
Seo Yun Moon +9 more
openaire +3 more sources
Cancer Medicine, 2020 Tamoxifen‐based hormone therapy is central for the treatment of estrogen receptor positive (ER+) breast cancer. However, the acquired tamoxifen resistance, typically co‐exists with hypoxia, remains a major challenge.
Ying Li +10 more
doaj +1 more source
Molecular Analysis of Acquired Tamoxifen Resistance in Breast Cancer Cell Line
Asian Pacific Journal of Cancer Biology, 2017 Background: Tamoxifen is an FDA approved drug for the prevention and the treatment of breast cancer, but its therapeutic benefit is limited by the development of drug resistance.
Mansour Abachi +4 more
doaj +3 more sources